Navigation Links
Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
Date:7/22/2008

Study Demonstrates Feasibility and Efficacy of Treating Patients with

Primary Liver Cancer

SAN FRANCISCO, and YONGIN-SI, South Korea, July 22 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), and its South Korean partner Green Cross Corp., announced today that novel findings from a Phase I clinical trial of its first-in-class lead product JX-594 demonstrated that the product was well-tolerated and resulted in clear anti-cancer efficacy in patients with liver cancer. Three patients with advanced treatment-refractory hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) were treated with JX-594. Objective radiographic responses were demonstrated. Serum tumor markers, which correlate with tumor burden over time in patients, decreased by up to 95 percent after treatment. JX-594 replication, its release into the circulation and distant tumor targeting and infection were demonstrated. JX-594 administration resulted in tumor vascular shutdown. Oncolytic virotherapy was also shown, for the first time, to suppress underlying HBV replication in HCC patients by over 50 percent in all three patients. A Phase II clinical trial is now underway for JX-594 in liver cancer. The data were published in the journal Molecular Therapy.

"These clinical results with JX-594 in end-stage liver cancer patients represent a major step forward for JX-594 against this difficult to treat cancer. We are excited by the potential to fulfill the huge unmet medical needs for these desperate patients with no curative treatment options, specifically by treating their tumors and potentially their underlying Hepatitis B viral infection. As a lead site for the on-going Phase II trial of JX-594 for liver cancer, we look forward to extending these results in a larger number of patients," said Dr. Tony Reid, M.D., Ph.D., Associate Professor and Director of Clinical Investigation at the University of California, San Diego Moores
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
2. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
5. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
6. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
7. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
10. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
11. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)...  University Hospitals (UH) Case Medical Center is ... area to implant a new miniaturized, wireless monitoring sensor to ... first and only FDA-approved heart failure monitoring device that has ... physicians to manage heart failure., The ... the pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:6/2/2015)... , June 2, 2015   PDI , ... today announced a series of corporate commitments designed ... to reduce the threat of antimicrobial-resistant microorganisms as ... Centers for Disease Control and Prevention (CDC) and ... to Combat Antibiotic-Resistant Bacteria. Along with ...
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/zkkg9q/blood_processing ) has announced ... - Global Strategic Business Report" report to their offering. ... US, Canada , Japan ... , Latin America , and Rest of ... 2014 through 2020. Also, a seven-year historic analysis is provided ...
Breaking Medicine Technology:UH Case Medical Center becomes first in region to offer patients a new heart failure monitoring solution 2UH Case Medical Center becomes first in region to offer patients a new heart failure monitoring solution 3PDI Partners with White House and Centers for Disease Control and Prevention (CDC) to Combat Antimicrobial Resistance 2Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 2Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 3
... Bend Research Inc. ( www.bendres.com ), a leading independent ... has received a new U.S. patent covering a process ... pressure nozzles. The patent, which adds ... can be used to make solid amorphous dispersions with ...
... Inc. Magazine Tuesday ranked PercipEnz ... an exclusive ranking of the nation,s fastest-growing private ... at the most important segment of the economy—America,s ... 7-Eleven, Brooklyn Brewery, and Radio Flyer, maker of ...
Cached Medicine Technology:Bend Research Receives Patent for Preparing Spray-Dried Drug Dispersions Using Pressure Nozzles 2PercipEnz Makes Inc. Magazine's Fourth Annual List of America's Fastest-Growing Private Companies—the Inc. 5000 2PercipEnz Makes Inc. Magazine's Fourth Annual List of America's Fastest-Growing Private Companies—the Inc. 5000 3PercipEnz Makes Inc. Magazine's Fourth Annual List of America's Fastest-Growing Private Companies—the Inc. 5000 4
(Date:6/3/2015)... June 03, 2015 Fit Body Boot ... camp fitness program. The company helps thousands of individuals across ... encourage more people to hit the gym and get the ... tips for getting the most out any gym membership: , ... about committing to gym memberships is saying motivated and on ...
(Date:6/3/2015)... Veatch Consulting Services is excited to announce ... for business in April 2006, they have made it ... clients. Each and every year they have worked diligently ... to say that they are off to a great ... added this year is the Customer Review site veatchconsultingreviews.weebly.com. ...
(Date:6/3/2015)... evigilo, a world leader in delivering ... new branding by launching a new and enhanced content-centric ... identity: the logo depicting a sun-like image with a ... – To Know. To Act. In time. The color ... A global, borderless approach to alerting and delivering safety ...
(Date:6/2/2015)... 2015 The organic cotton market is ... an annual study conducted by Textile Exchange, an international ... The report, released today, encompasses extensive data about organic ... level and also takes the opportunity to celebrate those ... , The last several years have been complicated ...
(Date:6/2/2015)... 02, 2015 Aidan Booth And ... to public yesterday, and has since received rave ... product reviewer Tiffany Hendricks has weighed in with ... the course on her website HonestyFirstReviews.com. , "These ... Internet marketers looking to hone their business skills ...
Breaking Medicine News(10 mins):Health News:Summer Body Slim-Down: 5 Ways to Avoid Quitting Gym Memberships this Summer 2Health News:Summer Body Slim-Down: 5 Ways to Avoid Quitting Gym Memberships this Summer 3Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 2Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 3Health News:Keep calm! evigilos' "sun" will come out tomorrow – to know, to act, in time. 2Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 2Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 3Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 4Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 5Health News:100K Factory - Review of Aidan Booth and Steve Clayton's New IM System Published 2
... The Society of Nuclear Medicine (SNM) commends the U.S. ... System Drugs Advisory Committee on its recent recommendation for ... agent, which is used in conjunction with positron emission ... the brain which may cause Alzheimer,s disease, is produced ...
... address the latest issues on the early detection of ... will host an international research consortium in Scottsdale, Ariz., ... Program, or I-ELCAP, is a lung cancer research organization ... 26 states and eight other countries whose mission ...
... Michigan Cardiovascular Center and the University of Pittsburgh have been ... devices for the large and growing group of Americans with ... Blood Institute and HeartWare International, a maker of left ventricular ... these devices that support the circulation of patients with failing ...
... MONDAY, Jan. 24 (HealthDay News) -- There,s a much greater ... they score just below a round number (such as 1200) than ... Researchers analyzed a set of SAT scores from 1994 to 2001 ... This indicates that students who got those scores were more likely ...
... Jan. 23 (HealthDay News) -- Sledding is one of ... certain safety precautions are needed in order to prevent ... recent year in which sledding injury data was available ... injuries treated at U.S. hospital emergency rooms, doctors, offices ...
... survive and thrive in its hiding spot within the human immune ... remains such a formidable foe after three decades of research ... it also offers scientists a new, unexpected way to try to ... of Rochester Medical Center and Emory University was published Dec. 10 ...
Cached Medicine News:Health News:SNM applauds FDA advisory committee recommendation for approval of Alzheimer's imaging agent 2Health News:Biodesign hosts international consortium on screening for lung cancer 2Health News:Study examines earlier use of heart pumps in growing group of heart failure patients 2Health News:Study examines earlier use of heart pumps in growing group of heart failure patients 3Health News:For Safe Sledding, Follow These Tips 2Health News:Unexpected find opens up new front in effort to stop HIV 2
Lyphochek Benzo/TCA Control Set A is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and tricyclic antidepressant drugs....
Lyphochek Benzo/TCA Control Set B is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and antidepressant drugs....
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
Lyphochek Endocrine Control is a human based product designed to monitor plasma catecholamine testing procedures by HPLC. The analytes are spiked at critical concentrations to cover the dynamic range...
Medicine Products: